Incretins · appetite signalling · body composition · clinical trials

GLP-1 medicines, retatrutide and muscle-preservation research

Medical weight management is moving beyond the vague phrase “weight-loss injection”. GLP-1, GIP and glucagon pathways affect appetite and metabolism, while a separate research field is asking whether activin/myostatin signalling can help preserve lean mass.

Educational body-composition illustration comparing general weight change, localised fat and loose skin — Scale weight, fat mass, lean mass, appetite, metabolic health and loose skin are related—but they are not the same outcome.

Start with the vocabulary

What is a GLP-1 medicine?

GLP-1 is a hormone signal involved in appetite, stomach emptying, insulin release and glucagon regulation. Medicines that activate the GLP-1 receptor can increase fullness and reduce food intake, but prescribing depends on the exact licensed product, indication and individual medical assessment.

Semaglutide is a GLP-1 receptor agonist. Tirzepatide activates both GIP and GLP-1 receptors. They should not be grouped with every emerging molecule as though the evidence, licences and risks are identical.

Mechanisms compared

Licensed pathways and investigational science are not the same

Scientific route	What it targets	Status in August 2026	What to understand
GLP-1 receptor agonists	The GLP-1 receptor, influencing appetite, gastric emptying and glucose-related signalling.	Some exact products and indications are licensed prescription medicines in the UK.	A licensed diabetes indication and a licensed weight-management indication are not automatically interchangeable. Suitability and supply must be lawful.
Dual GIP/GLP-1 agonism	Both GIP and GLP-1 receptors.	Tirzepatide is a prescription medicine with product-specific UK licences.	It is a dual agonist, not simply “a stronger GLP-1”. Side effects, contraindications, dose escalation and monitoring remain clinically important.
Retatrutide	A single molecule activating GIP, GLP-1 and glucagon receptors.	Investigational and not approved by any regulator. Lilly reported Phase 3 data in 2026, while further trials and regulatory work continue.	“GLP-3” is an inaccurate nickname. Lilly describes retatrutide as a triple hormone receptor agonist and warns against products sold outside clinical trials.
Myostatin / activin research	A signalling family involved in regulation of skeletal muscle and other tissues.	Research field; not a public weight-loss treatment category.	Blocking myostatin alone and blocking shared activin type II receptors are not identical strategies. Changes in lean mass do not automatically prove better strength, function or long-term outcomes.
Bimagrumab	A monoclonal antibody that blocks activin type II receptors, affecting signals including activins and myostatin.	Investigational. Lilly’s BELIEVE study was a randomised Phase 2 trial of bimagrumab, semaglutide and their combination in adults with overweight or obesity.	It is more accurate to call it an activin-receptor blocker than a simple “myostatin drug”. The Phase 2 results are research evidence, not a licence or a clinic offer.

Why lean mass has become a major research question

Weight loss usually includes a mixture of fat mass and fat-free mass. Researchers are studying whether nutrition, progressive resistance training and future medicines can improve body-composition outcomes while weight falls. Lean mass measured by scanning is not the same as muscle quality, strength, mobility or long-term health, so all of those outcomes matter.

The BELIEVE Phase 2 trial

BELIEVE (ClinicalTrials.gov NCT05616013) was sponsored by Eli Lilly and Versanis Bio. The study compared bimagrumab, semaglutide, their combination and placebo in adults with overweight or obesity. Its peer-reviewed report was published in Nature Medicine in March 2026. Bimagrumab is an investigational activin type II receptor-blocking antibody; it is not a licensed weight-management medicine.

What “Phase 2” and “Phase 3” mean

Phase 2

Tests dose, biological effect and safety in a selected population. A positive result still does not establish general availability.

Phase 3

Larger confirmatory trials designed to support a potential regulatory submission and better characterise benefit and risk.

Regulatory review

Regulators assess the full evidence, manufacturing and proposed indication. A press release is not an approval.

Licensed use

The exact product, indication, population and prescribing information define lawful clinical use.

Do not buy “research” retatrutide or bimagrumab online

Retatrutide is not approved for public use and Lilly states it is legally available only through its clinical trials. Products claiming to contain an investigational molecule may have unknown identity, purity or dose. Bimagrumab is also investigational.

Medical red flags during any regulated pathway

Severe or persistent abdominal pain, repeated vomiting, dehydration, fainting, chest symptoms, a serious allergic reaction, major mood change or another acute concern needs prompt medical assessment. Dose changes and medicine side effects belong with the prescribing team.